Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

Compass Pathways’ depression drug trial meets goals but falls short of investor hopes, triggering a sharp share selloff.

A common blood test can flag early Alzheimer's disease patients who are four times more likely to experience rapid brain ...

Compass Pathways says a single dose of its synthetic psilocybin significantly reduced depression symptoms in patients who ...

Compass Pathways said Monday it achieved its primary endpoint in an early readout from the largest-ever study of psilocybin ...

An Ontario-based mushroom company has teamed up with Arizona State University to advance psychedelic genome research.

The Multidisciplinary Association for Psychedelic Studies (MAPS) hosted this year's conference in Denver, the second time ...

Welcome back to the Daily Aviation for a new documentary video about the NASA Aero Spacelines Super Guppy, one of the oldest ...

Getting started on the new warehouse space: a 40x72 post frame building with a gambrel roof. The video covers the following ...